Atomo Diagnostics (ASX:AT1) Shares Drop: What Investors Should Know

Sonal Goyal

05 November 2026 01:55 PM AEDT

Atomo Diagnostics (ASX:AT1) Shares Drop: What Investors Should Know

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Shares traded at A$0.013 during the 5 November 2026 session, down 7.14%.
Revenue for Q1 FY27 was A$1.63 million, with growth of 140% over the prior comparable quarter.
Cash on hand at quarter end was A$2.67 million.

Shares in Atomo Diagnostics Limited (ASX:AT1) traded at A$0.013 during the Trading session on 5 November 2026, down 7.14% in the early afternoon. The S&P/ASX 200 was up 1.87%, trading near 9,000 points. Atomo develops rapid diagnostic tests, using its Galileo cassette platform, and its FebriDx product is one of its commercial lines. The company's latest update is its Q1 FY27 quarterly activity report and Appendix 4C, released on 29 October 2026.

Q1 FY27 Quarterly Report released 29 October 2026

Atomo reported Revenue of A$1.63 million for the quarter ended 30 September 2026, which the company said was growth of 140% over the comparable quarter in 2026. FebriDx orders were A$680,000 for the quarter, up 314% year on year. Cash receipts were A$2.51 million, including A$2.40 million from customers, and cash on hand at quarter end was A$2.67 million.

The company also signed an agreement with Innovation Scientific for a Generation 4 HIV product development program, and announced a Partnership with Upfront Diagnostics for a rapid brain disease test. Its Active Syphilis test completed technology transfer to manufacturing, with Clinical Trials planned for the new calendar year.

Sector context

At midday, the ASX Health Care sector was up 3.08%, while Atomo shares moved lower in the session. The quarterly report is dated 29 October and is not linked to the 5 November price move.

What to watch ahead

Attention will be on the start of clinical trials for the Active Syphilis test in the new calendar year, the development progress on the HIV product and the next quarterly Cash Flow report.

Risks

Atomo's revenue is concentrated in a small number of products, and growth can be uneven between quarters. Development programs and clinical trials carry technical and regulatory risk, and the company will need to manage its cash position as it funds product development. The shares are very low-priced and can move sharply.

Final Word

Atomo's latest quarter reports rising revenue, a larger partnership pipeline and a cash balance of A$2.67 million. The share price fell during the session, and the timing of trials and product milestones will shape the company's next phase.

FAQs

Q: Why did Atomo Diagnostics shares fall on 5 November 2026?

A: Shares traded at A$0.013, down 7.14%, during the session. The Q1 FY27 report is dated 29 October 2026 and is not linked to the price move.

Q: What was Atomo's Q1 FY27 revenue?

A: The company reported revenue of A$1.63 million for the quarter ended 30 September 2026.

Q: How much cash did Atomo have at quarter end?

A: Cash on hand at quarter end was A$2.67 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.